The CHI SQUARE Trial: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
|||
| Line 8: | Line 8: | ||
==Methods== | ==Methods== | ||
CHI-SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? This is a phase II, multi- | CHI-SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? This is a phase II, multi-centered, double-blinded, ascending dose, placebo-controlled, dose-finding trial of CER-001 or placebo in subjects with acute coronary syndromes. 504 patients were grouped into: placebo, low dose, mid dose, and high dose of CER-001 groups to receive a total of 6 infusions in 5 weeks. The total coronary plaque volume is measured with intravascular ultrasound (IVUS). | ||
==Results== | ==Results== | ||
Revision as of 11:27, 18 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
The CHI SQUARE Trial On the Web |
|
American Roentgen Ray Society Images of The CHI SQUARE Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To determine the safety and efficacy of CER-001 on atherosclerotic plaque progression and regression in patients with acute coronary syndromes.
Methods
CHI-SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? This is a phase II, multi-centered, double-blinded, ascending dose, placebo-controlled, dose-finding trial of CER-001 or placebo in subjects with acute coronary syndromes. 504 patients were grouped into: placebo, low dose, mid dose, and high dose of CER-001 groups to receive a total of 6 infusions in 5 weeks. The total coronary plaque volume is measured with intravascular ultrasound (IVUS).
Results
Pending